Leerink Partnrs Has Positive Outlook of KALV Q3 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at Leerink Partnrs raised their Q3 2026 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued on Monday, July 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.54) for the quarter, up from their prior forecast of ($0.56). The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals' Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.48) EPS and FY2027 earnings at ($1.17) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same period last year, the firm earned ($1.07) EPS.

Other equities research analysts have also issued research reports about the stock. Jones Trading restated a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday. JMP Securities raised their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, Leerink Partners raised their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $26.29.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded down $0.48 on Thursday, reaching $15.51. The company's stock had a trading volume of 1,983,930 shares, compared to its average volume of 565,271. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $16.45. The company has a market cap of $771.16 million, a P/E ratio of -4.17 and a beta of -0.04. The company has a 50-day simple moving average of $12.55 and a 200 day simple moving average of $11.19.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,169 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $14.50, for a total transaction of $103,950.50. Following the completion of the sale, the chief executive officer owned 315,074 shares in the company, valued at $4,568,573. This trade represents a 2.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider owned 106,611 shares of the company's stock, valued at $1,262,274.24. The trade was a 2.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,899 shares of company stock valued at $206,176 in the last quarter. 10.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC increased its position in KalVista Pharmaceuticals by 16.6% during the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after purchasing an additional 701,007 shares during the period. Tang Capital Management LLC increased its position in KalVista Pharmaceuticals by 13.2% during the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after purchasing an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. increased its position in KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP increased its position in KalVista Pharmaceuticals by 19.3% during the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares during the period. Finally, Vanguard Group Inc. increased its position in KalVista Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).